Please assess the completion status of the following clinical trial:

Trial Title: Drug-Eluting Balloon in Stable and Unstable Angina

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Informed written consent~* At least one of the following~  1. Patient is using oral anticoagulation (warfarin, dabigatran or rivaroxaban)~ 2. Anemia (hemoglobin below the threshold: \< 117g/l in women and \< 134 g/l in men) or thrombocytopenia (\<100) detected \<6 months prior the PCI~ 3. Active malign disease (metastatic cancer or ongoing radio- or chemotherapy)~ 4. Prior intracerebral hemorrhage or ischemic stroke~ 5. Severe kidney or liver dysfunction (eGFR \< 30ml/kg/min, liver cirrhosis, BIL \>2x over threshold or ALAT \>3x over threshold)~ 6. Elective surgery planned \< 12 months after the PCI~ 7. General frailty for e.g. because of long corticosteroid treatment or generalized cachexia (BMI \< 20 kg/m2)~ 8. Age ≥ 80 years~ 9. Inability or suspected inability to use DAPT for 12 months~* Either of the following:~  10) Prior bleeding (BARC 2-5)~ 1. Stable angina or dyspnea and a coronary narrowing causing myocardial ischemia detected in the angiogram. Ischemia is documented by the pressure wire measurement (FFR) or by a non-invasive test such as stress ECG test or perfusion imaging~ 2. ACS (UAP or NSTEMI): symptoms of heart ischemia ≥ 20 minutes and ≥ 0,5mm ST-depression or transient ST-elevation or T-wave inversion at least in two adjacent leads and/or a high sensitivity troponin (hs-tnt) rise at least one unit above the 99. percentile or at least 50% rise in hs-tnt between two samples taken 3 hours apart~* ≥1 de novo lesions in native coronary arteries or bypass vein grafts~* Reference diameter of the vessel is 2,5-4,0mm~* Lesion or lesions are suitable for PCI~Exclusion Criteria:~* Inability to give written consent~* STEMI~* Reference diameter of the vessel is \<2,5mm or \>4,0mm~* Bifurcation lesion requiring the stenting of the side branch~* Dissection affecting the flow (TIMI\<3) or significant recoil (\>30% in main branch, \>50% in side branch) after predilatation~* In-stent restenosis~* Life expectancy \< 12 months~* Cardiogenic shock at the arrival to the coronary angiography~* Uncertainty about neurological recovery e.g. after resuscitation~* Unprotected left main (LM) lesion~* Chronic total occlusion (CTO)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- drug-eluting balloon (DEB) (Type: EXPERIMENTAL): Patients treated with drug-eluting balloon (DEB). Provisional stenting with BMS is permitted in case of a flow-limiting dissection or significant recoil (\>30% in main branch and \>50% side-branch), Includes both stable CAD and ACS patients.
- bare-metal stent (BMS) (Type: ACTIVE_COMPARATOR): Patients treated with bare-metal stent (BMS). Includes both stable CAD and ACS patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues